Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.

The judge's ruling adds to a growing number of legal decisions halting or scaling back the administration’s actions.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Source: Getty Images Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials. Studies presented at the ASCO Annual Meeting 2025 ...

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.